NTRR: Global Cannabis Industry Continues Unprecedented Growth

LAS VEGAS, NV / ACCESSWIRE / April 14, 2016 / As Neutra Corp. (NTRR) works to deliver more and better products for cannabis patients and growers, the market for those products continues to expand rapidly around the world. According to a new white paper produced by the University of Sydney Business School and MCG Pharmaceuticals,... more →
Posted in: Press

Clinical Trials & Latest Studies Lead To Developments Indicating Cannabinoids

Today’s leading companies with recent developments of interest are Cannabis Science, Inc. (OTC: CBIS), Compass Diversified Holdings (NYSE: CODI ), NEMUS Bioscience, Inc. (OTC: NMUS), GW Pharmaceuticals (NASDAQ: GWPH ) and Insys Therapeutics, Inc. (NASDAQ: INSY ) Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing... more →
Posted in: Investing

GW Pharmaceuticals Is The Most Legit Among Marijuana Stocks

GW Pharmaceuticals or GWPH stock has exploded in the last year, up about eight-fold from spring 2013. But unfortunately, its valuation is based more on hope than anything since the company continues to operate in the red as it hopes for results to materialize from its drug pipeline. It’s one and only product, the marijuana-based... more →
Posted in: News

The Future Of The Marijuana Industry In The US of A

Arena is not alone in this growing field of cannabis-derived pharmaceuticals. In April 2015, GW Pharmaceuticals plc (LON: GLC) of London received orphan drug status for Epidiolex , a drug based on the cannabinoid CBD. It has shown promise in trials for helping to reduce the number of seizures in those suffering from severe epilepsy.... more →
Posted in: News

3 Marijuana Stocks To Watch As Featured On The Motley Fool

Subsys, used for breakthrough cancer pain in opioid-tolerant patients, is by far the company’s biggest-selling product, accounting for over 99% of total revenue. Insys also sells generic Dronabinol SG, a second-line cannabinoid drug used for chemotherapy-induced nausea and vomiting and anorexia associated with weight loss in... more →
Posted in: News

In The $850m Cannabis Testing Market, Signal Bay Makes Strategic Acquisition

Through its CANNAiQ(TM) B2B information portal, the company provides an enterprise version of MassRoots Inc.’s (OTCQB:MSRT) consumer platform. Signal Bay is investigating the proposed “research” license mentioned in Oregon’s HB3400, for example, which could lead to a move into the pharmaceutical side of the... more →
Posted in: Investing

Can Marijuana Treat Schizophrenia?

It’s long been held that marijuana use in its traditional form can lead to positive patient experiences, but confirming those personal testimonials in large, placebo-controlled studies has been tough to do. The difficulty in proving that marijuana can successfully treat disease was hammered home last week when GW Pharmaceuticals... more →
Posted in: Press

NTRR CEO to Network With Potential Clients at Oregon’s CannaGrow Expo

Neutra Corp.’s (NTRR) executive leadership will travel to Oregon next week to take part in the CannaGrow Expo in Portland, one of the country’s largest events dedicated to the science of growing cannabis. The two-day expo will feature an expo hall full of the latest tools and technology for horticulture, drawing cannabis growers,... more →
Posted in: Press

By Early 2016, GW Pharmaceuticals Could Get Approval From FDA

The drug, called Epidiolex, previously received fast-track status from the FDA and is now in the final Phase 3 study for pediatric epilepsy disorders, according to the Huffington Post. Results are expected in the first quarter of next year. Epidiolex is expected to “breeze through this final stage,” and it could be on the market... more →
Posted in: News
1 2 3 5